Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note published on Friday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.22 on Friday. The business has a fifty day moving average price of $0.28 and a two-hundred day moving average price of $0.33. The stock has a market capitalization of $4.64 million, a PE ratio of -0.03 and a beta of 0.85. Oragenics has a fifty-two week low of $0.21 and a fifty-two week high of $3.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.